Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Virginia Commonwealth University Identifier:
First received: September 30, 2011
Last updated: February 19, 2016
Last verified: February 2016
This phase I trial studies the side effects and best dose of giving pemetrexed disodium and sorafenib tosylate together in treating patients with advanced solid tumors. Pemetrexed disodium and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib tosylate may also stop the growth of solid tumors by blocking blood flow to the tumor. Giving pemetrexed disodium together with sorafenib tosylate may kill more tumor cells.

Condition Intervention Phase
Unspecified Adult Solid Tumor
Drug: sorafenib tosylate
Drug: pemetrexed disodium
Other: laboratory biomarker analysis
Procedure: biopsy
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Study of Pemetrexed and Sorafenib in Advanced Malignancy

Resource links provided by NLM:

Further study details as provided by Virginia Commonwealth University:

Primary Outcome Measures:
  • Recommended phase 2 doses for the combination of pemetrexed disodium with sorafenib tosylate [ Time Frame: At least 4 weeks ]
    Maximum doses of pemetrexed and sorafenib, which, when administered in combination are determined to be tolerable and will be tested in a Phase 2 trial for efficacy.

Secondary Outcome Measures:
  • Number of subjects in whom study treatment produces antitumor effects of the combination [ Time Frame: Up to 4 years ]
    Tumor masses will be evaluated for response according to the Response Evaluation Criteria In Solid Tumors (RECIST) Criteria v 1.1

  • Number of biopsy specimens that successfully stain for Beclin1 [ Time Frame: Baseline up to 4 weeks ]
    Determine if biopsy specimens can be stained and analyzed for Beclin1. Assessed by use of a repeated measure analysis through a linear mixed model, as well as an ordinal regression analysis.

  • Number of biopsy specimens that can be analyzed for PDGFRb expression [ Time Frame: Baseline up to 4 weeks ]
    Assessed by use of a repeated measure analysis through a linear mixed model, as well as an ordinal regression analysis.

  • Analysis of pTEN expression in biopsy specimens [ Time Frame: Baseline up to 4 weeks ]
    Assessed by use of a repeated measure analysis through a linear mixed model, as well as an ordinal regression analysis.

Enrollment: 37
Study Start Date: October 2011
Study Completion Date: September 2015
Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (enzyme inhibitor therapy, antiangiogenesis)
Patients receive pemetrexed disodium IV on day 1 every 2 weeks and sorafenib tosylate PO BID for 4 weeks on days 1-5. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Drug: sorafenib tosylate
Given PO
Other Names:
  • BAY 43-9006
  • BAY 43-9006 Tosylate Salt
  • BAY 54-9085
  • Nexavar
  • SFN
Drug: pemetrexed disodium
Given IV
Other Names:
  • LY231514
  • MTA
Other: laboratory biomarker analysis
Correlative studies
Procedure: biopsy
Optional correlative studies
Other Name: biopsies

Detailed Description:


I. To determine doses for the combination of pemetrexed (pemetrexed disodium) with sorafenib (sorafenib tosylate) appropriate for Phase II study.


I. To evaluate the safety, tolerance, and toxicity of the combination of pemetrexed and sorafenib.

II. To observe antitumor effects of the combination.

OUTLINE: This is a dose-escalation study of pemetrexed disodium and sorafenib tosylate.

Patients receive pemetrexed disodium intravenously (IV) on day 1 every 2 weeks and sorafenib tosylate orally (PO) twice daily (BID) on days 1-5. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 30 days.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Advanced solid tumor malignancy for which there is no potentially curative treatment; there is no limit to the number of prior lines of therapy
  • Performance status Eastern Cooperative Oncology Group (ECOG) equal or less than 1
  • Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3 x upper institutional limit (ULN)
  • Total bilirubin =< 1.5 ULN
  • Creatinine clearance (CrCl) >= 45 mL/min as measured by the standard Cockcroft-Gault equation
  • International normalized ratio (INR) =< 1.5 (if not due to anticoagulants)
  • White blood cell count (WBC) >= 3,000 cells/mm3
  • Absolute neutrophil count (ANC) >= 1,500 cells/mm3
  • Platelets >= 100,000 cells/mm3
  • Hemoglobin (Hgb) >= 8.5 g/dL
  • Prior toxicities are allowed as long as they are stable and would not interfere with study drug toxicity assessment
  • Measurable or evaluable disease by Response Evaluation Criteria In Solid Tumors (RECIST) (v 1.1)
  • Ability to understand and the willingness to sign a written informed consent document; a signed informed consent must be obtained prior to any study specific procedures
  • Women of childbearing potential must have a negative pregnancy test performed within 7 days prior to the start of treatment; women of childbearing potential and men must agree to use a medically accepted form of birth control for the duration of study participation; men must agree to use a medically accepted form of birth control for 2 months following completion of study treatment

Exclusion Criteria:

  • Any investigational agent within 4 weeks of first dose of study treatment
  • Unwillingness or inability to take folic acid, vitamin B12, or dexamethasone
  • Known or presumed intolerance of pemetrexed or sorafenib; unable to swallow medication; suspected malabsorption
  • Active illicit substance or alcohol abuse
  • Contraindication to antiangiogenic agents, including:
  • Pulmonary hemorrhage/bleeding event >= Grade 2 within 4 weeks or less prior to the first dose of study drug
  • Any other hemorrhage/bleeding event >= Grade 3 within 4 weeks or less prior to the first dose of study drug
  • Serious non-healing wound, ulcer, or bone fracture
  • Thrombolic or embolic events such as a myocardial infarction, cerebrovascular accident including transient ischemic attacks within the past 6 months
  • Major cardiac dysfunction, such as uncontrolled angina, congestive heart failure with New York Heart Association (NYHA) class III or higher, ventricular arrhythmias requiring anti-arrhythmic therapy
  • Systolic blood pressure > 160 mmHg or diastolic pressure > 100 mmHg despite optimal medical management
  • Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents for a 5 day period
  • Serious uncontrolled infection > Common Terminology Criteria for Adverse Events (CTCAE) (v 4) grade 2
  • Peripheral motor or sensory neuropathy>CTCAE (v4) grade 2
  • Uncontrolled metastatic brain disease
  • Serum B12 or folate levels below the institution's lower limit of normal. Patients may begin B12/folic acid supplementation and can be reconsidered for study once levels meet the eligibility requirements
  • Administration of non-steroidal anti-inflammatory drugs (NSAIDs) within 5 days prior to pemetrexed dosing (note: if a candidate routinely takes NSAIDs prior to enrollment, consider transition to alternate non-NSAID for duration of study treatment, if possible).
  • Other condition(s) that in the opinion of the investigator might compromise the objectives of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01450384

United States, Virginia
Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, United States, 23298
Sponsors and Collaborators
Virginia Commonwealth University
National Cancer Institute (NCI)
Principal Investigator: Andrew Poklepovic Massey Cancer Center
  More Information

Additional Information:
Responsible Party: Virginia Commonwealth University Identifier: NCT01450384     History of Changes
Other Study ID Numbers: MCC-13874
NCI-2011-03035 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
P30CA016059 ( US NIH Grant/Contract Award Number )
Study First Received: September 30, 2011
Last Updated: February 19, 2016

Keywords provided by Virginia Commonwealth University:
protocol specific

Additional relevant MeSH terms:
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors processed this record on May 25, 2017